Revilla2003 - Controlling HIV infection using recombinant viruses
This a model from the article:
Fighting a virus with a virus: a dynamic model for HIV-1 therapy.
Revilla T, Garcia-Ramos G. Math Biosci
2003 Oct;185(2):191-203 12941536
,
Abstract:
A mathematical model examined a potential therapy for controlling viral
infections using genetically modified viruses. The control of the infection is
an indirect effect of the selective elimination by an engineered virus of
infected cells that are the source of the pathogens. Therefore, this engineered
virus could greatly compensate for a dysfunctional immune system compromised by
AIDS. In vitro studies using engineered viruses have been shown to decrease the
HIV-1 load about 1000-fold. However, the efficacy of this potential treatment
for reducing the viral load in AIDS patients is unknown. The present model
studied the interactions among the HIV-1 virus, its main host cell (activated
CD4+ T cells), and a therapeutic engineered virus in an in vivo context; and it
examined the conditions for controlling the pathogen. This model predicted a
significant drop in the HIV-1 load, but the treatment does not eradicate HIV. A
basic estimation using a currently engineered virus indicated an HIV-1 load
reduction of 92% and a recovery of host cells to 17% of their normal level.
Greater success (98% HIV reduction, 44% host cells recovery) is expected as more
competent engineered viruses are designed. These results suggest that therapy
using viruses could be an alternative to extend the survival of AIDS patients.
This model was taken from the CellML repository
and automatically converted to SBML.
The original model was:
Revilla T, Garcia-Ramos G. (2003) - version=1.0
The original CellML model was created by:
Catherine Lloyd
c.lloyd@auckland.ac.nz
The University of Auckland
This model originates from BioModels Database: A Database of Annotated Published Models (http://www.ebi.ac.uk/biomodels/). It is copyright (c) 2005-2011 The BioModels.net Team.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication
for more information.
In summary, you are entitled to use this encoded model in absolutely any manner you deem suitable, verbatim, or with modification, alone or embedded it in a larger context, redistribute it, commercially or not, in a restricted way or not..
To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92.
-
Fighting a virus with a virus: a dynamic model for HIV-1 therapy.
- Revilla T, García-Ramos G
- Mathematical biosciences , 10/ 2003 , Volume 185 , pages: 191-203 , PubMed ID: 12941536
- Instituto de Zoología Tropical, Universidad Central de Venezuela, Apdo. Postal 47058, Caracas 1041-A, Venezuela.
- A mathematical model examined a potential therapy for controlling viral infections using genetically modified viruses. The control of the infection is an indirect effect of the selective elimination by an engineered virus of infected cells that are the source of the pathogens. Therefore, this engineered virus could greatly compensate for a dysfunctional immune system compromised by AIDS. In vitro studies using engineered viruses have been shown to decrease the HIV-1 load about 1000-fold. However, the efficacy of this potential treatment for reducing the viral load in AIDS patients is unknown. The present model studied the interactions among the HIV-1 virus, its main host cell (activated CD4+ T cells), and a therapeutic engineered virus in an in vivo context; and it examined the conditions for controlling the pathogen. This model predicted a significant drop in the HIV-1 load, but the treatment does not eradicate HIV. A basic estimation using a currently engineered virus indicated an HIV-1 load reduction of 92% and a recovery of host cells to 17% of their normal level. Greater success (98% HIV reduction, 44% host cells recovery) is expected as more competent engineered viruses are designed. These results suggest that therapy using viruses could be an alternative to extend the survival of AIDS patients.
Submitter of this revision: Rahuman Sheriff
Modellers: Camille Laibe, Rahuman Sheriff
Metadata information
isDescribedBy (1 statement)
hasTaxon (2 statements)
hasProperty (3 statements)
Experimental Factor Ontology HIV infection
Experimental Factor Ontology treatment
occursIn (1 statement)
Connected external resources
SBGN view in Newt Editor
| Name | Description | Size | Actions |
|---|---|---|---|
Model files |
|||
| MODEL1006230047.xml | SBML L2V4 representation of Revilla2003 - Controlling HIV infection using recombinant viruses | 45.62 KB | Preview | Download |
Additional files |
|||
| MODEL1006230047-biopax2.owl | Auto-generated BioPAX (Level 2) | 1.04 KB | Preview | Download |
| MODEL1006230047-biopax3.owl | Auto-generated BioPAX (Level 3) | 1.98 KB | Preview | Download |
| MODEL1006230047.m | Auto-generated Octave file | 2.93 KB | Preview | Download |
| MODEL1006230047.pdf | Auto-generated PDF file | 136.13 KB | Preview | Download |
| MODEL1006230047.png | Auto-generated Reaction graph (PNG) | 5.04 KB | Preview | Download |
| MODEL1006230047.sci | Auto-generated Scilab file | 245.00 Bytes | Preview | Download |
| MODEL1006230047.svg | Auto-generated Reaction graph (SVG) | 851.00 Bytes | Preview | Download |
| MODEL1006230047.vcml | Auto-generated VCML file | 900.00 Bytes | Preview | Download |
| MODEL1006230047.xpp | Auto-generated XPP file | 1.73 KB | Preview | Download |
| MODEL1006230047_curated_annotated.cps | COPASI file to reproduce Figure 2b of the reference publication | 66.89 KB | Preview | Download |
| MODEL1006230047_urn.xml | Auto-generated SBML file with URNs | 13.14 KB | Preview | Download |
- Model originally submitted by : Camille Laibe
- Submitted: Jun 23, 2010 10:12:12 AM
- Last Modified: Aug 30, 2018 4:40:10 PM
Revisions
-
Version: 5
- Submitted on: Aug 30, 2018 4:40:10 PM
- Submitted by: Rahuman Sheriff
- With comment: Automatically added model identifier BIOMD0000000707
-
Version: 2
- Submitted on: Jun 25, 2010 2:13:26 PM
- Submitted by: Camille Laibe
- With comment: Current version of Revilla2003_HIV1therapy
-
Version: 1
- Submitted on: Jun 23, 2010 10:12:12 AM
- Submitted by: Camille Laibe
- With comment: Original import of Revilla2003_HIV1therapy
(*) You might be seeing discontinuous
revisions as only public revisions are displayed here. Any private revisions
of this model will only be shown to the submitter and their collaborators.
: Variable used inside SBML models
| Species | Initial Concentration/Amount |
|---|---|
| Single Infected Th Cells helper T-lymphocyte ; infected cell |
6.0 mol |
| Recombinant Virus Genetically Modified Organism ; Viruses |
1.0 mol |
| Double Infected Th Cells infected cell ; helper T-lymphocyte |
0.0 mol |
| Normal Th cells helper T-lymphocyte |
3.0 mol |
| Pathogen Virus Human immunodeficiency virus 1 |
149.0 mol |
| Reactions | Rate | Parameters |
|---|---|---|
| Normal_Th_cells => Single_Infected_Th_Cells; Pathogen_Virus | Plasma*beta*Normal_Th_cells*Pathogen_Virus | beta = 0.004 |
| => Recombinant_Virus; Double_Infected_Th_Cells | Plasma*c*Double_Infected_Th_Cells | c = 2000.0 |
| Recombinant_Virus => | Plasma*q*Recombinant_Virus | q = 2.0 |
| Single_Infected_Th_Cells => Double_Infected_Th_Cells; Recombinant_Virus | Plasma*alpha*Recombinant_Virus*Single_Infected_Th_Cells | alpha = 0.004 |
| Normal_Th_cells => | Plasma*d*Normal_Th_cells | d = 0.01 |
| Pathogen_Virus => | Plasma*u*Pathogen_Virus | u = 2.0 |
| Double_Infected_Th_Cells => | Plasma*b*Double_Infected_Th_Cells | b = 2.0 |
| => Normal_Th_cells | Plasma*lamda | lamda = 2.0 |
(added: 29 Aug 2018, 16:27:28, updated: 29 Aug 2018, 16:27:28)